Aberrant TGF-β activation and signaling can promote tumorigenesis by stimulating epithelial-mesenchymal transition (EMT), angiogenesis, cancer-associated fibroblast activation, and immunosuppression within the TME (42, 50–52) (Figure 2). Here, TGFB1 is linked to cancer.